GSK315234 / GSK - LARVOL DELTA

Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-oncostatin M monoclonal antibody in rheumatoid arthritis: Results from phase II randomized, placebo-controlled trials (Arthritis Res Ther) - P2, N=135; NCT00674635; Sponsor: GlaxoSmithKline; "An exploratory analysis of clinical, pharmacokinetic and pharmacodynamics data suggests the lack of efficacy may be due to moderate binding affinity and rapid off-rate of GSK315234 as compared to the higher affinity OSM receptor causing a protein carrier effect prolonging the half life of OSM due to accumulation of the OSM/antibody complex in the serum and synovial fluid."

P2 data • Immunology • Rheumatoid Arthritis